UroGen Pharma/URGN

$17.96

5.09%
-
1D1W1MYTD1YMAX

About UroGen Pharma

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Ticker

URGN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Elizabeth Barrett

Employees

192

Headquarters

Ra'anana, Israel

UroGen Pharma Metrics

BasicAdvanced
$527.51M
Market cap
-
P/E ratio
-$4.25
EPS
1.08
Beta
-
Dividend rate

What the Analysts think about UroGen Pharma

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
121.33% upside
High $54.00
Low $18.00
$17.96
Current price
$39.75
Average price target

UroGen Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-104.8% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$20.8M
-1.42%
Net income
$-21.8M
-9.54%
Profit margin
-104.8%
-8.24%

UroGen Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 19.62%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$1.22
-$1.30
-$1.03
-$0.68
-
Expected
-$1.07
-$1.33
-$1.14
-$0.85
-$0.68
Surprise
13.66%
-2.26%
-9.33%
-19.62%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell UroGen Pharma stock

Buy or sell UroGen Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing